Patents by Inventor Adam Judge
Adam Judge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12251470Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: GrantFiled: November 8, 2019Date of Patent: March 18, 2025Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Petra Schreiner
-
Publication number: 20240316206Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: April 25, 2024Publication date: September 26, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 12043833Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: GrantFiled: June 30, 2022Date of Patent: July 23, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
-
Publication number: 20240207462Abstract: Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 and 110 kDa. The immunoconjugates can be used to deliver alpha and beta emitters for the treatment of tumors or cancer.Type: ApplicationFiled: August 17, 2023Publication date: June 27, 2024Inventors: Adam JUDGE, Michael ABRAMS, Alexander Laurence MANDEL, Raja Solomon VISWAS
-
Patent number: 12016929Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: January 12, 2024Date of Patent: June 25, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20240148875Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: January 12, 2024Publication date: May 9, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20240100166Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: September 5, 2023Publication date: March 28, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 11786598Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: July 25, 2022Date of Patent: October 17, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20230248831Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: July 25, 2022Publication date: August 10, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20230110295Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: ApplicationFiled: June 30, 2022Publication date: April 13, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
-
Patent number: 11446383Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: August 22, 2018Date of Patent: September 20, 2022Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 11427823Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: GrantFiled: April 10, 2018Date of Patent: August 30, 2022Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
-
Publication number: 20220168222Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.Type: ApplicationFiled: April 24, 2020Publication date: June 2, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
-
Publication number: 20220160899Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: ApplicationFiled: November 1, 2021Publication date: May 26, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
-
Publication number: 20220031847Abstract: The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.Type: ApplicationFiled: November 4, 2019Publication date: February 3, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Kieu Mong LAM
-
Publication number: 20220000778Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Petra SCHREINER
-
Patent number: 11191849Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: GrantFiled: June 30, 2017Date of Patent: December 7, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. Abrams, James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Stephen P. Reid, Edward D. Yaworski
-
Publication number: 20200407724Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: ApplicationFiled: April 10, 2018Publication date: December 31, 2020Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
-
Publication number: 20190240339Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: August 22, 2018Publication date: August 8, 2019Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20190240354Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: ApplicationFiled: June 30, 2017Publication date: August 8, 2019Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI